Associated equity: Molecule Group
Molecule Group (formerly Vulcan Two) is consolidating the private prescription sector of the regulated UK ePharmacy market. The group currently consists of CloudRx, Hyperdrug and Webmed.
Molecule Group – Company introduction (external video)
Molecule Group – Interim results (external video)
Molecule Group — 1 video in collection
In this interview, Michael Kraftman, CEO of Molecule Group, introduces the company and outlines its buy-and-build strategy for the UK private online pharmacy market. He discusses recent fundraisings, the acquisitions of CloudRx, Webmed and Hyperdrug, the growth drivers in private healthcare, opportunities to improve customer retention and operational efficiency, and Molecule’s longer-term acquisition and growth ambitions.
Michael Kraftman: I founded Molecule, which was actually founded as Vulcan Two Group, a code name. Together with my COO, Brendan O’Brien, we’d built up Vision Direct, which is Europe’s largest seller of contact lenses online. We sold that to Essilor in 2016 and carried on working there for another six years or so.
When we left, we wanted to do something else together. We looked at other markets that had similarities, and online pharmacy, or e-pharmacy, was the number one category that made a lot of sense. The thing about the contact lens business was that it was a recurring business. We were selling disposable products that people needed every day. It was also a regulated business, which meant that it kept a lot of parties out of it. You had to conform with regulation, which kind of controlled competition.
E-pharmacy had all those characteristics and, attractively, had not been very penetrated online. Prescriptions only went electronic in 2019, which meant that the online pharmacy market was really very late to develop in the UK. We then had to go and fund it. We’d built Vision Direct very much through a combination of acquisitions (I actually bought Brendan’s business in 2009), and we combined very strong organic growth with a series of further acquisitions. We did nine acquisitions over the whole life of that company, and we wanted to follow that same format and formula.
Obviously, that meant raising money to buy the initial businesses. We were going around mainly to private equity investors to seek funding for the concept. We went to Hargreave Hale VCT, which was one of the Vision Direct investors. The investment manager there liked the project but said, because they were now part of Canaccord, ‘I actually think Canaccord could do the whole thing for you.’ He introduced me to their capital markets team, and we did some test marketing around May last year. That went well, and Canaccord put together the concept of floating the business as it was, as a cash shell, to raise enough money to take the pipeline of deals we’d developed all the way through to completion, including the legal work and due diligence.
We did the real roadshow in August and raised £12m as a cash shell. At the beginning of September, we were live on AIM. So, it all happened very quickly after quite a lot of time going around the private equity market prior to that, but it worked out extremely well. With that funding in place, we developed the acquisition pipeline. We’d actually gone out with the initial admission document describing six deals in broad terms, and we took three of those all the way through to completion.
We did all the due diligence and legal work, signed the sale and purchase agreements conditional on a further fundraising, and did our second roadshow at the end of February and beginning of March this year. We completed those acquisitions and simultaneously raised a further £40m on AIM. We were then a real trading business.
Michael Kraftman: We bought three businesses, as I said, and the largest one by far was CloudRx. CloudRx is a business-to-business platform where we have a network of around 1,500 prescribing partners. They’re individual doctors and large clinical groups, and they send their prescriptions to us electronically. We fulfil them and send the medication directly to their patients. The attractive part of that business is that it has technical integration with the practice management systems those prescribers use. That’s a real value-add and a barrier to entry in terms of competition.
We’re plumbed into the majority of practice management systems. We convince those clinics and doctors to use our service, and all they have to do is turn the switch on in their system. The prescriptions then flow to us rather than being printed out on pieces of paper. That’s a really attractive business.
One thing we haven’t actually said so far is that we’re only in the private market. We’re not servicing NHS prescriptions. These clinics and doctors are writing private prescriptions, which have traditionally been very manual. The NHS went electronic in 2019, but the private market was left to do its own thing. The vendor of the CloudRx business was instrumental in developing the application programming interfaces (APIs), and that’s basically the key technology we acquired.
We have a very significant business where we’re receiving these prescriptions and fulfilling them. We also have a relationship with the patient because the patient actually pays us. We send them an email or text link as soon as we receive the prescription from the doctor. They click on the link, make a payment using their credit card, and then we send the medication out.
One of the projects we’ve got is to develop that relationship. We’re going to transform that payment page into a full e-commerce checkout. If you’ve got a prescription for a drug that needs to be fulfilled, very much like a physical pharmacy, you’ll be encouraged to perhaps put other things into your basket at the same time. That’s a key aspect of the business development model we’ve got for the business.
The other two businesses are direct-to-consumer businesses, where we’re marketing directly to the public and encouraging people to come to us, very much like a typical e-commerce business. The first of those was Webmed, now rebranded as Molecule Clinic. There, we’re actually marketing the service of doing an online consultation with the customer, who then becomes a patient. That business is very significantly focused on weight loss, which has been one of the huge drivers of the private market in the UK. But we also provide other treatments typically called lifestyle treatments, such as erectile dysfunction and sexually transmitted diseases, and things that people might not be comfortable going to a doctor about. That business is very strong, and we’re developing and professionalising its e-commerce aspects, improving the marketing and so on. That very much fits our model of winning a patient through marketing but keeping them through very good service. That business is growing extremely well.
The final business is veterinary medicine. It was called Hyperdrug and is now called Molecule Veterinary. We service pet owners but not just pet owners. We also serve a lot of businesses involved with horses, including stables, and farm animals. We’re fulfilling both prescription and non-prescription drugs in that business, so it’s a combination of prescription and what’s known as over-the-counter medication.
We’re expanding that in two ways. One is that we’re developing API integration with veterinary practice management systems. We’ll be able to introduce effectively a business-to-business offering where we receive prescriptions directly from vets, which is a very attractive business.
The Competition and Markets Authority (CMA) recently reported on the veterinary market in the UK and is basically going to be enforcing a separation between the provision of veterinary services and the provision of medication. That’s falling right into our hands, so it’s a perfect time to enter that marketplace.
We’re also looking to expand the over-the-counter side of the business into human medication.
When we bought those businesses, we didn’t actually have a human over-the-counter business. But we’re going to develop the e-commerce platform we acquired from Hyperdrug into the human market.
Michael Kraftman: First of all, the NHS market is actually more developed than the private market in terms of online fulfilment. As I mentioned earlier, prescriptions went electronic in 2019, and several scale players have already entered the marketplace. There are very large players in there, so there’s a greater level of competition. But the other aspect is that the economics are very challenging.
When you’re an NHS pharmacy, whether online or on the high street, your revenue is governed by the NHS drug tariff. It’s fixed. You only receive a fixed amount for every single drug. Your margins are controlled by how well you can do your buying because you’re making a margin between a fixed selling price and what you can acquire the drugs for.
But it’s a bit of a cat-and-mouse game. The government is always adjusting the drug tariff to reduce the margin to whatever it can. If prices improve and cost prices reduce, the drug tariff will obviously go down to capture that benefit. In addition, the drug tariff can be quite slow to respond to price increases, so it’s not uncommon for pharmacists to have to sell drugs at a loss, which is obviously very unattractive. Further, with e-commerce, the NHS rules mandate that an online pharmacy isn’t allowed to charge for delivery, which makes the economics even more challenging than they are for the high street.
Obviously, you incur a delivery cost. When you’re selling controlled drugs, you have to send them by a tracked method, so there are even more costs associated with that, and you simply cannot recoup any of those costs from the patient. So, the economics are very challenging. Those large-scale e-pharmacies don’t tend to make money on their NHS business. They may be profitable at an organisation level, but that’s only because they’ve entered the private market in addition. Those core NHS businesses are not profitable, and we want to stay well out of that.
Now, the private market has grown very dramatically in the UK over the last few years, and there are several drivers. One is the lifestyle medications I mentioned. There’s a whole series of medications that the NHS doesn’t provide at all, or provides in a very constrained way, and people have gone private to get those medications. One of the core areas of the original CloudRx business was hormone replacement therapy (HRT) for women. The NHS does provide HRT but tends to provide it in a constrained way.
Oestrogen is commonly prescribed on the NHS and readily available, but the other two drugs, progesterone and testosterone, are not, and there’s a little bit of a postcode lottery. In some areas women can get them, and in others they can’t. A lot of women have turned to the private market to get those additional drugs, and quite a lot actually get the whole thing from private providers because it’s easy to do so. That’s been a very strong growth driver of the private market, and it’s just one of the areas that the NHS has tended to vacate.
The NHS has rules and looks at what it considers to be cost-effective, determining that those other drugs don’t provide sufficient benefit to warrant the extra cost. But obviously, individual women want to make the decision to pay for those treatments themselves. Other areas include sensitive conditions such as sexually transmitted diseases and erectile dysfunction. A lot of the time, people are uncomfortable going to their GP and prefer to get treatment privately through an online consultation.
Attention deficit hyperactivity disorder (ADHD) is another area where the NHS has found it very difficult to meet demand. There’s been a very large increase in private fulfilment of ADHD medication as the number of diagnoses has increased dramatically over the last few years. That whole group of medications is one driver, but there’s a second very major driver, and that’s the reduction in the quality of NHS GP services.
I think everybody now experiences the fact that if you want to get an appointment with an NHS GP, you have to phone at 8am on the dot. If you leave it until two minutes past eight, you’ve missed your chance of an appointment. You try again at lunchtime or the next morning. In response, private insurers have started to provide GP appointments of much higher quality.
Most NHS appointments are now over the telephone, with two- or three-minute appointments with your doctor, whereas private appointments tend to be on video, are much longer and provide a much higher-quality experience.
Most of the large insurers, Bupa and AXA PPP, for example, include those appointments for no extra charge within the premiums that privately insured people pay. The economics for them must be that if people get diagnosed earlier, they’re more likely to have lower costs down the line from paying expensive consultants. They want to get their insured patients diagnosed quickly and into the medical system rather than leaving them needing treatment. So, there’s a really big driver towards private GP provision.
The last figures we have, from 2024, suggest that about 14% of all GP appointments were provided privately, which is extraordinary growth. Private GPs tended to be used by a very small minority of people. The typical private insurance model in the UK was that you went to your NHS GP, and if you needed a referral to a consultant, you said, ‘I’ve got private medical insurance,’ and they referred you to a private consultant. That model is breaking down, and people are now going to a private consultation to start with.
The way the NHS rules work is that if you have a private appointment with a GP, there has to be a private prescription that follows. So, the number of private prescriptions for general medication is growing very rapidly in the UK. We’ve got these twin drivers of lifestyle medication, including treatments that aren’t readily available on the NHS, and general medication, where the private provision of GP appointments is leading to private prescriptions.
Michael Kraftman: Service. The great thing about the Vision Direct business, which we sold to Essilor in 2016 at a very good multiple, was that our revenue was so predictable. We got to a point where 85% of our revenue came from repeat customers. Those customers came back to us because our service was extraordinarily good. We surprised people with how good it was, and that meant the revenue was very predictable.
It also meant our marketing costs were really very low because we were only marketing to the 15% of new business that we needed to continue the organic growth. The growth was very strong because that 15% of new customers compounded. They came in, stayed with us, and the next year we’d add another 15%. So, you got very strong growth because all those cohorts of customers you’d won in previous years were just repeating. It was a very strong model of compounding growth.
Prescription medication falls exactly into that model. It’s actually better. With contact lenses, people tend to drop out in their late 40s as they need reading glasses. There are multifocal contact lenses, but the majority of people tend to drop out of contact lenses.
With medication, it’s the opposite. People need more as they get older. If somebody is prescribed statins in their 50s, you’ve got 30 or 40 years of lifetime value in that customer on those drugs. So, it’s very attractive from that point of view.
One of the key things we’re doing is building a new fulfilment centre in Leeds. It’s going to go live before the end of the year. We’re going to introduce the sort of service levels we provided at Vision Direct. At Vision Direct, you could order up to about quarter to midnight on a Sunday and receive your contact lenses on Monday. That type of service surprised customers, and it kept them.
So, although when you go to market for new business, you do have to be price competitive and win customers in a competitive environment, we tended to keep our customers based on service. That’s the key element we’re going to introduce into this business. We’re going to make sure we develop that reputation. In fact, when we were raising money for Vision Direct, we’d done our last large acquisition. We were actually called Get Lenses until 2014. Then we bought a business that was larger than ourselves called Vision Direct, and we rebranded the whole business as Vision Direct because the research told us it was a better brand.
When we did the funding round for that, a lot of the people we were seeing were our customers, and that helped because they just got it. They understood the service levels. One of our investors actually described it as ‘witchcraft’. He couldn’t understand how he could order so late on a Sunday and get his contact lenses the next day. It was all about attention to detail. We were able to achieve that because we had a quarter-past-midnight collection on Monday morning from Royal Mail. It was effectively same-day delivery. That sort of attention to detail, and focusing on the service, is really what’s going to differentiate us going forward.
Michael Kraftman: It’s the back end, the warehouse. As I mentioned, we’re building it, and it’s going to be ready by the end of the year. We’re introducing, alongside the physical facility, a brand-new enterprise resource planning (ERP) system. That’s going to be integrated with the front-end e-commerce platforms and the business-to-business API systems we’ve acquired.
But that’s a huge amount of work. It’s not that visible, but behind the scenes it’s actually more work than the physical building of the infrastructure. So, there’s a huge amount to do in the next six weeks, and we’re very focused on getting that done.
Michael Kraftman: We’re going to focus purely on the UK. With Vision Direct, we’d actually expanded into seven European countries by the time we sold it, and most of those European markets were entered through an acquisition. The difference is that the contact lens market in the UK is only about £650m. So, to get to a scale business, we really did need to go Europe-wide.
We ended up with 10% of the entire contact lens market in the UK, so we were reaching a sort of saturation level.
The online market was only about a third of the total contact lens market, so we had a third of that. The prescription market in the UK is massively larger. The total prescription market, and this is quite a wide range, is somewhere between £15bn and £20bn. The reason it’s such a wide range is that the weight-loss business has grown so rapidly that it’s overtaking the speed at which these market statistics come out.
The weight-loss business itself in the UK is reported to be in the region of £2bn–4bn. That’s obviously affecting the total market size. But even without weight loss, you’re looking at a business that’s about £14bn. So, there’s a massive amount of growth that can be achieved in the UK. If we get to 10% of the market, it would be a £2bn business, so there’s plenty of growth. That’s where we’re focusing.
In terms of what other businesses we’re looking to buy, we’re looking to fill the gaps we have. We’re looking at potentially acquiring over-the-counter medication businesses, as I mentioned. We’re also looking at other lifestyle medication businesses, both B2B and B2C. There are some specialised B2B companies that focus on a very narrow segment, which makes a lot of sense to bolt onto us. There are also other clinical businesses that actually conduct online consultations. So, we’re looking at all three areas, basically.
Michael Kraftman: It will need to be a further raise from the market if we’re coming back to make acquisitions. When we did the first and second funding rounds, our investors obviously expected us to be able to come back. Part of the attraction of the business is that they can back a company they can actually make further investments into.
We’re profitable and generating cash, but the EBITDA we’re generating is very small relative to the likely funding requirements for acquisitions. We have said that we’re only going to raise money for further deals. We don’t need to raise money for our operations because the business is profitable.
Michael Kraftman: In terms of growth rates, with our last business we got to a growth rate of 40% organically, with acquisitions on top. That’s the sort of model we’re looking to follow.
I’ve said this in our roadshows: there will be a £1bn online pharmacy in the UK. I can’t say we’ll definitely be it, but I think we’ve got the aspirations to get to that sort of size, and that is our objective.
If we can get to 40% organic growth and do acquisitions on top, then you could be looking at doubling quite comfortably every year. That’s the expectation. We just need to get on and execute at the moment. As I’ve said, there’s a lot to get on with and do. We’re very excited about the opportunity, for sure.
This transcript has been lightly edited for clarity and readability. Verbal fillers, false starts and minor repetitions have been removed from the interviewee’s responses only. Punctuation, spelling and formatting have also been standardised in line with Edison house style. No substantive changes have been made to the meaning of the discussion.